Inhibition of IGF-1R in adrenocortical carcinoma
作者： Francesco Boccardo
DOI:
关键词: Stopping rules 、 Adrenocortical carcinoma 、 Oncology 、 Selection (genetic algorithm) 、 Best interests 、 Internal medicine 、 Medicine
摘要: 356 www.thelancet.com/oncology Vol 16 April 2015 early-phase data to ensure target inhibition clinical eff ect, selection of appropriate endpoints for randomised phase 2 and 3 studies, identifi cation rigorous stopping rules that would protect patients from undue exposure toxicity ineff ective treatments. However, the true lesson learn this study is biomedical research cannot ignore best interests patients, nor should developmental pathways drugs be rushed inappropriately.
参考文章(16)
Brian J. Druker, Imatinib as a paradigm of targeted therapies. Advances in Cancer Research. ,vol. 91, pp. 1- 30 ,(2004) , 10.1016/S0065-230X(04)91001-9
Martin Fassnacht, Massimo Terzolo, Bruno Allolio, Eric Baudin, Harm Haak, Alfredo Berruti, Staffan Welin, Carmen Schade-Brittinger, André Lacroix, Barbara Jarzab, Halfdan Sorbye, David J Torpy, Vinzenz Stepan, David E Schteingart, Wiebke Arlt, Matthias Kroiss, Sophie Leboulleux, Paola Sperone, Anders Sundin, Ilse Hermsen, Stefanie Hahner, Holger S Willenberg, Antoine Tabarin, Marcus Quinkler, Christelle De La Fouchardière, Martin Schlumberger, Franco Mantero, Dirk Weismann, Felix Beuschlein, Hans Gelderblom, Hanneke Wilmink, Monica Sender, Maureen Edgerly, Werner Kenn, Tito Fojo, Hans-Helge Müller, Britt Skogseid, None, Combination Chemotherapy in Advanced Adrenocortical Carcinoma The New England Journal of Medicine. ,vol. 366, pp. 2189- 2197 ,(2012) , 10.1056/NEJMOA1200966
Ferdous M. Barlaskar, Aaron C. Spalding, Joanne H. Heaton, Rork Kuick, Alex C. Kim, Dafydd G. Thomas, Thomas J. Giordano, Edgar Ben-Josef, Gary D. Hammer, Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma The Journal of Clinical Endocrinology and Metabolism. ,vol. 94, pp. 204- 212 ,(2009) , 10.1210/JC.2008-1456
Lawrence S. Kirschner, The next generation of therapies for adrenocortical cancers Trends in Endocrinology & Metabolism. ,vol. 23, pp. 343- 350 ,(2012) , 10.1016/J.TEM.2012.04.001
Christine Gicquel, Marie-Laure Raffin-Sanson, Véronique Gaston, Xavier Bertagna, Pierre-François Plouin, Martin Schlumberger, Albert Louvel, Jean-Pierre Luton, Yves Le Bouc, Structural and Functional Abnormalities at 11p15 Are Associated with the Malignant Phenotype in Sporadic Adrenocortical Tumors: Study on a Series of 82 Tumors The Journal of Clinical Endocrinology and Metabolism. ,vol. 82, pp. 2559- 2565 ,(1997) , 10.1210/JCEM.82.8.4170
Jeanny B. Aragon-Ching, Ravi A. Madan, William L. Dahut, Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises Journal of Oncology. ,vol. 2010, pp. 361836- 361836 ,(2010) , 10.1155/2010/361836
J.Y. Henry, L. Lu, M. Adams, B. Meyer, J.B. Bartlett, A.G. Dalgleish, C. Galustian, Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. The Prostate. ,vol. 72, pp. 856- 867 ,(2012) , 10.1002/PROS.21488
Alice T. Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J. Solomon, Fiona Blackhall, Yi-Long Wu, Michael Thomas, Kenneth J. O'Byrne, Denis Moro-Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne, Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer The New England Journal of Medicine. ,vol. 368, pp. 2385- 2394 ,(2013) , 10.1056/NEJMOA1214886
Chadi Nabhan, Anand Patel, Dana Villines, Kathy Tolzien, Susan K. Kelby, Timothy M. Lestingi, Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study. Clinical Genitourinary Cancer. ,vol. 12, pp. 27- 32 ,(2014) , 10.1016/J.CLGC.2013.09.001
Frank Worden, David Olmos, Donghua Yin, David Schteingart, Gretchen N. Batzel, M. Luisa Paccagnella, Johann S. de Bono, Antonio Gualberto, Gary D. Hammer, Paul Haluska, Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma Cancer Chemotherapy and Pharmacology. ,vol. 65, pp. 765- 773 ,(2010) , 10.1007/S00280-009-1083-9